Financhill
Sell
30

XNCR Quote, Financials, Valuation and Earnings

Last price:
$7.58
Seasonality move :
14.69%
Day range:
$7.26 - $7.71
52-week range:
$7.16 - $27.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.12x
P/B ratio:
0.86x
Volume:
1M
Avg. volume:
1M
1-year change:
-68.61%
Market cap:
$547.3M
Revenue:
$110.5M
EPS (TTM):
-$3.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XNCR
Xencor
$24.8M -$0.58 -5.5% -34.49% $28.20
AMGN
Amgen
$8B $4.26 5.5% 281.73% $314.20
CPRX
Catalyst Pharmaceuticals
$131.1M $0.53 14.43% 64.07% $34.00
PSTV
Plus Therapeutics
$1.1M -$0.29 -- -54.22% $9.83
RARE
Ultragenyx Pharmaceutical
$144.5M -$1.64 9.48% -13.24% $89.89
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $797.21
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XNCR
Xencor
$7.69 $28.20 $547.3M -- $0.00 0% 4.12x
AMGN
Amgen
$271.90 $314.20 $146.2B 24.81x $2.38 3.41% 4.31x
CPRX
Catalyst Pharmaceuticals
$24.11 $34.00 $2.9B 15.36x $0.00 0% 5.67x
PSTV
Plus Therapeutics
$0.31 $9.83 $5.3M -- $0.00 0% 0.38x
RARE
Ultragenyx Pharmaceutical
$35.51 $89.89 $3.4B -- $0.00 0% 5.62x
REGN
Regeneron Pharmaceuticals
$596.85 $797.21 $64.4B 15.19x $0.88 0.3% 4.83x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XNCR
Xencor
-- 2.752 -- 5.74x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
CPRX
Catalyst Pharmaceuticals
-- 0.175 -- 5.85x
PSTV
Plus Therapeutics
-- -0.140 -- --
RARE
Ultragenyx Pharmaceutical
-- 1.162 -- 2.03x
REGN
Regeneron Pharmaceuticals
6.33% 0.973 2.89% 3.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XNCR
Xencor
-- -$43.2M -30.26% -32.34% -120.98% -$17.7M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
CPRX
Catalyst Pharmaceuticals
$123.5M $63.4M 29.43% 29.43% 44.81% $60M
PSTV
Plus Therapeutics
-- -$3.8M -- -- -- -$3.7M
RARE
Ultragenyx Pharmaceutical
$110.6M -$142.9M -205.06% -205.06% -97.23% -$182.8M
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M

Xencor vs. Competitors

  • Which has Higher Returns XNCR or AMGN?

    Amgen has a net margin of -147.92% compared to Xencor's net margin of 21.23%. Xencor's return on equity of -32.34% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About XNCR or AMGN?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 266.71%. On the other hand Amgen has an analysts' consensus of $314.20 which suggests that it could grow by 15.56%. Given that Xencor has higher upside potential than Amgen, analysts believe Xencor is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    AMGN
    Amgen
    10 14 2
  • Is XNCR or AMGN More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock XNCR or AMGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.41% to investors and pays a quarterly dividend of $2.38 per share. Xencor pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or AMGN?

    Xencor quarterly revenues are $32.7M, which are smaller than Amgen quarterly revenues of $8.1B. Xencor's net income of -$48.4M is lower than Amgen's net income of $1.7B. Notably, Xencor's price-to-earnings ratio is -- while Amgen's PE ratio is 24.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.12x versus 4.31x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.12x -- $32.7M -$48.4M
    AMGN
    Amgen
    4.31x 24.81x $8.1B $1.7B
  • Which has Higher Returns XNCR or CPRX?

    Catalyst Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 40.12%. Xencor's return on equity of -32.34% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    CPRX
    Catalyst Pharmaceuticals
    87.34% $0.45 $794.3M
  • What do Analysts Say About XNCR or CPRX?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 266.71%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 41.02%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is XNCR or CPRX More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

  • Which is a Better Dividend Stock XNCR or CPRX?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or CPRX?

    Xencor quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Xencor's net income of -$48.4M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Xencor's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 15.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.12x versus 5.67x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.12x -- $32.7M -$48.4M
    CPRX
    Catalyst Pharmaceuticals
    5.67x 15.36x $141.4M $56.7M
  • Which has Higher Returns XNCR or PSTV?

    Plus Therapeutics has a net margin of -147.92% compared to Xencor's net margin of --. Xencor's return on equity of -32.34% beat Plus Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    PSTV
    Plus Therapeutics
    -- -$0.37 --
  • What do Analysts Say About XNCR or PSTV?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 266.71%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 3041.64%. Given that Plus Therapeutics has higher upside potential than Xencor, analysts believe Plus Therapeutics is more attractive than Xencor.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    PSTV
    Plus Therapeutics
    1 1 0
  • Is XNCR or PSTV More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

  • Which is a Better Dividend Stock XNCR or PSTV?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or PSTV?

    Xencor quarterly revenues are $32.7M, which are larger than Plus Therapeutics quarterly revenues of --. Xencor's net income of -$48.4M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Xencor's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.12x versus 0.38x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.12x -- $32.7M -$48.4M
    PSTV
    Plus Therapeutics
    0.38x -- -- -$2.9M
  • Which has Higher Returns XNCR or RARE?

    Ultragenyx Pharmaceutical has a net margin of -147.92% compared to Xencor's net margin of -108.46%. Xencor's return on equity of -32.34% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    RARE
    Ultragenyx Pharmaceutical
    79.42% -$1.57 $151.2M
  • What do Analysts Say About XNCR or RARE?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 266.71%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.89 which suggests that it could grow by 153.15%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    RARE
    Ultragenyx Pharmaceutical
    12 1 0
  • Is XNCR or RARE More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.284%.

  • Which is a Better Dividend Stock XNCR or RARE?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or RARE?

    Xencor quarterly revenues are $32.7M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Xencor's net income of -$48.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.12x versus 5.62x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.12x -- $32.7M -$48.4M
    RARE
    Ultragenyx Pharmaceutical
    5.62x -- $139.3M -$151.1M
  • Which has Higher Returns XNCR or REGN?

    Regeneron Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 26.7%. Xencor's return on equity of -32.34% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.66 $639.9M
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About XNCR or REGN?

    Xencor has a consensus price target of $28.20, signalling upside risk potential of 266.71%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 33.57%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    REGN
    Regeneron Pharmaceuticals
    14 4 0
  • Is XNCR or REGN More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

  • Which is a Better Dividend Stock XNCR or REGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.3% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or REGN?

    Xencor quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Xencor's net income of -$48.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.12x versus 4.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    4.12x -- $32.7M -$48.4M
    REGN
    Regeneron Pharmaceuticals
    4.83x 15.19x $3B $808.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Why Did Forge Global Stock Go Down?
Why Did Forge Global Stock Go Down?

Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
66
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
54
AAP alert for May 23

Advance Auto Parts [AAP] is down 0.98% over the past day.

Buy
67
IONQ alert for May 23

IonQ [IONQ] is down 0.48% over the past day.

Buy
75
URBN alert for May 23

Urban Outfitters [URBN] is down 1.24% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock